Genetic marker may predict need for aggressive ALL treatment in children

09/5/2013 | Oncology Nurse Advisor online

The presence of four or more copies of the gene RUNX1 in an abnormal chromosome 21 among children with acute lymphoblastic leukemia was associated with poor outcomes, according to a study in the Journal of Clinical Oncology. This gene amplification "helps identify patients who need more therapy than they may otherwise get," study author Dr. Stephen Hunger said.

View Full Article in:

Oncology Nurse Advisor online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC